Cargando…

Receptor-Mediated Endocytosis of α-Galactosidase A in Human Podocytes in Fabry Disease

Injury to the glomerular podocyte is a key mechanism in human glomerular disease and podocyte repair is an important therapeutic target. In Fabry disease, podocyte injury is caused by the intracellular accumulation of globotriaosylceramide. This study identifies in the human podocyte three endocytic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prabakaran, Thaneas, Nielsen, Rikke, Larsen, Jakob V., Sørensen, Søren S., Rasmussen, Ulla Feldt-, Saleem, Moin A., Petersen, Claus M., Verroust, Pierre J., Christensen, Erik I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3176300/ https://www.ncbi.nlm.nih.gov/pubmed/21949853 http://dx.doi.org/10.1371/journal.pone.0025065

Ejemplares similares

Mannose 6-Phosphate Receptor and Sortilin Mediated Endocytosis of α-Galactosidase A in Kidney Endothelial Cells
por: Prabakaran, Thaneas, et al.
Publicado: (2012)

Significant hearing loss in Fabry disease: Study of the Danish nationwide cohort prior to treatment
por: Yazdanfard, Puriya Daniel, et al.
Publicado: (2019)

Dysregulated Autophagy Contributes to Podocyte Damage in Fabry’s Disease
por: Liebau, Max C., et al.
Publicado: (2013)

α-Galactosidase a Deficiency in Fabry Disease Leads to Extensive Dysregulated Cellular Signaling Pathways in Human Podocytes
por: Jehn, Ulrich, et al.
Publicado: (2021)

Hearing loss in fabry disease: A 16 year follow-up study of the Danish nationwide cohort
por: Yazdanfard, Puriya Daniel Würtz, et al.
Publicado: (2022)

Fabry Disease and Early Stroke
por: Feldt-Rasmussen, U.
Publicado: (2011)

Fabry disease, respiratory symptoms, and airway limitation – a systematic review
por: Svensson, Camilla Kara, et al.
Publicado: (2015)

Optimizing human α-galactosidase for treatment of Fabry disease
por: Hallows, William C., et al.
Publicado: (2023)

Adipocytes participate in storage in α-galactosidase deficiency (Fabry disease)
por: Hůlková, Helena, et al.
Publicado: (2010)

Mosaicism of Podocyte Involvement Is Related to Podocyte Injury in Females with Fabry Disease
por: Mauer, Michael, et al.
Publicado: (2014)

Current concepts of the podocyte in nephrotic syndrome
por: Ding, Wen Y., et al.
Publicado: (2012)

Podocyte Endocytosis in Regulating the Glomerular Filtration Barrier
por: Tian, Xuefei, et al.
Publicado: (2022)

Accumulation of α-synuclein mediates podocyte injury in Fabry nephropathy
por: Braun, Fabian, et al.
Publicado: (2023)

Plasma mutant α-galactosidase A protein and globotriaosylsphingosine level in Fabry disease
por: Tsukimura, Takahiro, et al.
Publicado: (2014)

A Novel α-Galactosidase A Splicing Mutation Predisposes to Fabry Disease
por: Li, Ping, et al.
Publicado: (2019)

Rats deficient in α-galactosidase A develop ocular manifestations of Fabry disease
por: Miller, James J., et al.
Publicado: (2019)

Urinary Podocyte Loss Is Increased in Patients with Fabry Disease and Correlates with Clinical Severity of Fabry Nephropathy
por: Fall, Brent, et al.
Publicado: (2016)

Globotriaosylsphingosine Accumulation and Not Alpha-Galactosidase-A Deficiency Causes Endothelial Dysfunction in Fabry Disease
por: Namdar, Mehdi, et al.
Publicado: (2012)

A Novel Frameshift Mutation of Galactosidase-alpha in Fabry Disease Restricted to Dermatologic Manifestations
por: Kim, Dae Hun, et al.
Publicado: (2013)

Affective and cognitive behavior in the alpha-galactosidase A deficient mouse model of Fabry disease
por: Hofmann, Lukas, et al.
Publicado: (2017)

Early decrease in the podocalyxin to synaptopodin ratio in urinary Fabry podocytes
por: Trimarchi, Hernán, et al.
Publicado: (2018)

Expression of uPAR in Urinary Podocytes of Patients with Fabry Disease
por: Trimarchi, Hernán, et al.
Publicado: (2017)

Positron Emission Tomography and Magnetic Resonance Imaging of the Brain in Fabry Disease: A Nationwide, Long-Time, Prospective Follow-Up
por: Korsholm, Kirsten, et al.
Publicado: (2015)

Podocyte RhoGTPases: new therapeutic targets for nephrotic syndrome?
por: Saleem, Moin A., et al.
Publicado: (2019)

Recent advances in understanding autoimmune thyroid disease: the tallest tree in the forest of polyautoimmunity
por: Bliddal, Sofie, et al.
Publicado: (2017)

Correction: Globotriaosylceramide Accumulation and Not Alpha-Galactosidase-A Deficiency Causes Endothelial Dysfunction in Fabry Disease
por: Namdar, Mehdi, et al.
Publicado: (2012)

Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant
por: Lenders, Malte, et al.
Publicado: (2016)

Human α-Galactosidase A Mutants: Priceless Tools to Develop Novel Therapies for Fabry Disease
por: Modrego, Andrea, et al.
Publicado: (2021)

α-Galactosidase A Augmentation by Non-Viral Gene Therapy: Evaluation in Fabry Disease Mice
por: Rodríguez-Castejón, Julen, et al.
Publicado: (2021)

Curcumin Has Beneficial Effects on Lysosomal Alpha-Galactosidase: Potential Implications for the Cure of Fabry Disease
por: Monticelli, Maria, et al.
Publicado: (2023)

Sorting Nexin 9 facilitates podocin endocytosis in the injured podocyte
por: Sasaki, Yu, et al.
Publicado: (2017)

Podocyte Dedifferentiation: A Specialized Process for a Specialized Cell
por: May, Carl James, et al.
Publicado: (2014)

Data supporting the regulation of FOXC2 in podocyte dysfunction
por: Datta, Neeta, et al.
Publicado: (2016)

Long-term follow-up of renal function in patients treated with migalastat for Fabry disease
por: Bichet, Daniel G., et al.
Publicado: (2021)

Identification of a Missense Mutation in the α-galactosidase A Gene in a Chinese Family with Fabry Disease
por: Wu, Yuan, et al.
Publicado: (2018)

The New Pharmacological Chaperones PBXs Increase α-Galactosidase A Activity in Fabry Disease Cellular Models
por: Besada, Pedro, et al.
Publicado: (2021)

Drug Repositioning for Fabry Disease: Acetylsalicylic Acid Potentiates the Stabilization of Lysosomal Alpha-Galactosidase by Pharmacological Chaperones
por: Monticelli, Maria, et al.
Publicado: (2022)

Systematic cascade screening in the Danish Fabry Disease Centre: 20 years of a national single-centre experience
por: Effraimidis, Grigoris, et al.
Publicado: (2022)

Correction: Systematic cascade screening in the Danish Fabry Disease Centre: 20 years of a national single-centre experience
por: Effraimidis, Grigoris, et al.
Publicado: (2023)

Improvement of gastrointestinal symptoms in a significant proportion of male patients with classic Fabry disease treated with agalsidase beta: A Fabry Registry analysis stratified by phenotype
por: Hopkin, Robert J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2vlfqls4a8hi0slkco5bobtcn6